Charles River Associates

Overview

Charles River Associates (CRA), doing business as CRA International (NASDAQ: CRAI), is a global consulting firm providing economic, financial, and management consulting services. In life sciences/pharma, they offer expert analysis for strategy, pricing, market access, policy, and litigation support to pharmaceutical and biotech companies, law firms, and regulators. They apply rigorous analytics to high-stakes issues like portfolio strategy, payer negotiations, HEOR evidence planning, and regulatory impacts, but do not provide operational patient services like prior auth or copay programs.

Services & Capabilities

• Corporate/portfolio/brand strategy
• pricing & market access (launch pricing, payer negotiations, value proposition, HEOR evidence plans, innovative contracts)
• policy analysis
• litigation support
• rare disease strategy
• medical affairs
• advanced analytics. [CRA Life Sciences](https://www.crai.com/in

Competitive Position

• Deep industry knowledge with 25+ years experience
• rigorous analytic techniques from academic economists
• objective fact-based advice for high-stakes litigation/regulatory matters. CRA Life Sciences

Recent Developments

Record FY2025 revenue $751.6M (+9.3%), Q4 best ever; growth in antitrust, energy, IP. FY2026 guidance positive. Share repurchase expansion $45M (Feb 2025). No patient services news. National Today Feb 2026, Investing.com Q2 2025

Client & Partner Ecosystem

“Leading pharmaceutical companies” (unnamed); commissioned by GSK for policy report; collaborated with Janssen (J&J) on innovation study. CRA site

Technology Platform

HCAP; Pipeline Scout, SWAT

Therapeutic Focus

Rare disease, oncology, cell & gene therapy

Target Customers

Pharmaceutical/biotech companies, law firms, regulatory agencies

Sources

• CRA.com, CRA Life Sciences, LinkedIn, Management Consulted, MarketBeat CRAI, Wikipedia